Canonic Announced Full Commercial Launch of its First Medical Cannabis Products in Israel

REHOVOT, Israel, – Canonic Ltd., focused on the development of medical cannabis products and a  subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced the full commercial launch of its first two medical cannabis products, known as G200 and G150, following positive feedback received from patients during the company’s pre-launch campaign. These products were originally expected to be released to market during 2022.

Canonic’s first launched products, G200 and G150, are part of the G-nnovation product line under Canonic’s Meta Yield product program. Canonic’s G200 product will be available under the T20/C4 category[1] and G150 will be available under the T15/C3 category[2], according to the product categories established by the Israeli Ministry of Health. These products are based on cannabis varieties that were selected and developed using Evogene’s computational platform to express high levels of THC[3] and premium consumer traits[4].

In September and October 2021, Canonic conducted a pre-launch campaign, during which G200 and G150 were marketed in Israel to a limited number of licensed patients through selected pharmacies. Following positive feedback in the pre-launch campaign, indicating high patient satisfaction with the quality and positive effect of the products, Canonic decided to move ahead with the full commercial launch of these products in Israel. This was ahead of the original scheduled launch, which had been planned for 2022. These products will be widely available to consumers in pharmacies across Israel, from the day of this announcement.

With respect to product production for next year, as disclosed in the past, Canonic’s business model, which is based on producing products through external growers and manufacturers, provides the company relative flexibility in meeting demand in the market.

There are more than 100,000 licensed patients in Israel that consumed approximately 27 tons of cannabis in the first 8 months of 2021[5], and the total medical cannabis market in Israel is estimated at $260 million per year[6]. According to industry estimates, based on current growth rates, the number of patients in the Israeli market is expected to more than double by 2025.[7]

Dr. Arnon Heyman, CEO of Canonic, stated: “We are very excited to have reached this milestone ahead of target. This follows the very encouraging market feedback we received from patients, indicating potential market demand for our products. Our launch marks a key milestone in bringing closer our vision to become a world-leading medical cannabis company. We see today’s launch in Israel as only the beginning of our journey and our longer-term goal is to expand into additional markets abroad, with the European markets being our next target.”

Mr. Ofer Haviv, Chairman of Canonic and CEO & President of Evogene, stated: “I am pleased to see that within a very short time Canonic has built an impressive operation, with the launch of its first commercial-scale sales of medical cannabis. We are proud of the key role that Evogene played in this achievement, supporting product development using our unique platform and computational biology tech engine, GeneRator AI. We look forward to Canonic continuing to meet and exceed expectations and goals on its way to delivering exceptional products to patients.”

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or words of similar meaning. For example, Evogene and Canonic are using forward-looking statements in this press release when they discuss Canonic’s production plans and capabilities for 2022, its plans to expand its operations and penetrate to additional markets, and the expected growth in the cannabis market and number of patients. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

[1] T20/C4 category means 17%-24% THC & 1%-7% CBD.[2] T15/C3 category means 11%-19% THC & 0.5%-5.5% CBD.[3] Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis and one of at least 113 total cannabinoids identified in the plant.[4] Such traits may include inflorescence size, density, scent and overall appearance.[5] Please note the source is in Hebrew: https://www.health.gov.il/Subjects/cannabis/Documents/licenses-status-august-2021.pdf[6] https://finance.walla.co.il/item/3428846[7] Please note the source is in Hebrew: https://www.bizportal.co.il/capitalmarket/news/article/786443

(This information is primarily sourced from Canonic.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).